PDGFRB and pancreatic adenocarcinoma: Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has great activity against pancreatic cancer in a phase I trial [49]. Hence, our prognostic model may be used for optimizing individualized treatments for PAAD patients.